home / stock / tvtx / tvtx quote
Last: | $5.325 |
---|---|
Change Percent: | -2.29% |
Open: | $5.5 |
Close: | $5.45 |
High: | $5.5 |
Low: | $5.12 |
Volume: | 600,347 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$5.325 | $5.5 | $5.45 | $5.5 | $5.12 | 600,347 | 04-25-2024 |
$5.45 | $5.78 | $5.45 | $5.78 | $5.34 | 1,983,107 | 04-24-2024 |
$5.74 | $5.85 | $5.74 | $5.96 | $5.71 | 1,244,602 | 04-23-2024 |
$5.85 | $5.77 | $5.85 | $5.935 | $5.705 | 1,098,084 | 04-22-2024 |
$5.72 | $5.73 | $5.72 | $5.91 | $5.575 | 946,781 | 04-19-2024 |
$5.8 | $5.97 | $5.8 | $6.02 | $5.775 | 972,749 | 04-18-2024 |
$5.99 | $6.24 | $5.99 | $6.34 | $5.94 | 1,313,927 | 04-17-2024 |
$6.15 | $6.23 | $6.15 | $6.36 | $6.1128 | 792,112 | 04-16-2024 |
$6.32 | $6.33 | $6.32 | $6.49 | $6.19 | 1,547,751 | 04-15-2024 |
$6.37 | $6.65 | $6.37 | $6.7 | $6.25 | 1,409,832 | 04-12-2024 |
$6.69 | $6.74 | $6.69 | $6.845 | $6.52 | 1,966,022 | 04-11-2024 |
$6.67 | $6.84 | $6.67 | $6.84 | $6.4301 | 3,591,112 | 04-10-2024 |
$6.86 | $7.02 | $6.86 | $7.26 | $6.815 | 755,112 | 04-09-2024 |
$6.96 | $7.07 | $6.96 | $7.15 | $6.935 | 534,602 | 04-08-2024 |
$7.04 | $6.84 | $7.04 | $7.13 | $6.65 | 715,668 | 04-05-2024 |
$6.95 | $7.09 | $6.95 | $7.17 | $6.92 | 1,082,096 | 04-04-2024 |
$6.98 | $6.97 | $6.98 | $7.15 | $6.85 | 1,253,836 | 04-03-2024 |
$7.04 | $7.34 | $7.04 | $7.34 | $7 | 1,051,661 | 04-02-2024 |
$7.31 | $7.71 | $7.31 | $7.77 | $7.24 | 1,069,816 | 04-01-2024 |
$7.71 | $7.74 | $7.71 | $7.98 | $7.41 | 776,017 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
Travere Therapeutics Inc Com Company Name:
TVTX Stock Symbol:
NASDAQ Market:
First non-immunosuppressive therapy for the treatment of IgA nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Study SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) ...
CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy Canada NewsWire First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditi...
2024-04-15 06:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...